21 September 2018
Visiongain has launched a new pharma report: Global Acute Myeloid Leukaemia Market Report : Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib.
Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults and among the most lethal. In the United States, the annual incidence of AML is 19 000 new cases, and the incidence of AML-associated deaths is 10 000.
The rapid increase in geriatric population is one of the major drivers for the acute myeloid leukaemia market. With age, patients become highly susceptible to diseases due to decreased immunity and degeneration. As per an article published by NCBI, Acute myeloid leukaemia (AML) is the common form of acute leukaemia in adults, accounting for over 80% of all acute leukaemia in those over the age of 18 years.
The lead analyst of the report commented "The growth of the acute myeloid leukaemia market is estimated to be catalysed by opportunities in emerging markets due to improving healthcare infrastructure, unmet healthcare needs, rise in chronic diseases, and increased awareness of treatment methods.
There is a need for better therapeutics and treatment options. The increasing incidence and lack of better treatment options pose a lucrative opportunity for the market to grow and expand."
Leading companies featured in the report include Bristol-Myers Squibb Company, Celgene, Clavis Pharma ASA, Daiichi Sankyo, Eisai, GSK, Novartis, Roche, Sunesis Pharmaceuticals, Teva
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Automation is a rising trend in the supply chain as a way to reduce time to market and enhance efficiency. Automation is appealing for a variety of reasons, the most important of which is that it reduces human contact and hence interference.
02 September 2021
As governments in emerging countries are taking measures to improve healthcare, it is positively impacting the anti-epileptic drugs market growth.
24 August 2021
From a long-term perspective, the rapid growth of the mid-class economy will enhance the demand for OTC products in emerging economies such as China, India and Brazil.
24 August 2021
Growing female population with faecal incontinence to fuel bowel management systems market growth through 2031.